Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease.

@article{Terryah2018EvaluationOA,
  title={Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease.},
  author={Shawn T Terryah and Robert C. Fellner and Saira Ahmad and Patrick J. Moore and Boris Reidel and Juliana I. Sesma and Christine Seulki Kim and Alaina L. Garland and David W. Scott and Juan R. Sabater and Jerome Carpenter and Scott H. Randell and Mehmet Kesimer and William M. Abraham and William J. Arendshorst and Robert Tarran},
  journal={American journal of physiology. Lung cellular and molecular physiology},
  year={2018},
  volume={314 1},
  pages={
          L192-L205
        }
}
In cystic fibrosis (CF) lungs, epithelial Na+ channel (ENaC) hyperactivity causes a reduction in airway surface liquid volume, leading to decreased mucocilliary clearance, chronic bacterial infection, and lung damage. Inhibition of ENaC is an attractive therapeutic option. However, ENaC antagonists have failed clinically because of off-target effects in the… CONTINUE READING